Fortive Allowance for Doubtful Accounts Receivable (Current) decreased by 2.1% to $18.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 37.4%, from $29.40M to $18.40M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -15.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $38.40M | $36.30M | $39.70M | $39.40M | $37.90M | $41.50M | $43.90M | $41.20M | $40.40M | $39.60M | $39.20M | $33.10M | $27.80M | $29.40M | $19.40M | $29.40M | $27.20M | $18.70M | $18.80M | $18.40M |
| QoQ Change | — | -5.5% | +9.4% | -0.8% | -3.8% | +9.5% | +5.8% | -6.2% | -1.9% | -2.0% | -1.0% | -15.6% | -16.0% | +5.8% | -34.0% | +51.5% | -7.5% | -31.3% | +0.5% | -2.1% |
| YoY Change | — | — | — | — | -1.3% | +14.3% | +10.6% | +4.6% | +6.6% | -4.6% | -10.7% | -19.7% | -31.2% | -25.8% | -50.5% | -11.2% | -2.2% | -36.4% | -3.1% | -37.4% |